Search
Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia
He describes how Legend is no longer capacity constrained for it's CAR-T treatment, Carvykti, and previews the upcoming ASH conference.
2 days ago
Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.
CEO Michael Henderson walks us through what will be a busy year for the company. Coverage brought to you by
3 days ago
Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS. Coverage brought to you by
3 days ago
Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for more
CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans. Coverage brought to you by
3 days ago
Celcuity released what it believes is practice changing breast cancer data with its multi-target PAM inhibitor. Co-Founder & CEO Brian Sullivan describes why he believes the data is so important
He discusses the pathway and gedatolisib's ability to cover it holistically. Plus, future plans for filing and additional data in breast cancer and beyond. Coverage brought to you by
4 days ago
Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination than current therapies for IBD and rheumatology
CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD. Coverage brought to you by
4 days ago
Vicore Pharma is leveraging its understanding of the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond
CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting this summer. Coverage brought to you by
4 days ago
The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date scheduled for Hunter's Syndrome and a pivotal trial readout in DMD
CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs. Coverage brought to you by
4 days ago
Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome next year, and is also working on weight loss
Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis. Coverage brought to you by
4 days ago
Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile.
CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile. Coverage brought to you by
4 days ago
Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins
Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.
6 days ago
Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.
Nov 8
Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1
CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.
Nov 8
Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.
Nov 8
Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC
Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.
Nov 7
Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
Nov 7
Miami Oncology Summit: TuHURA Biosciences is trying to overcome resistance to cancer immunotherapies by trying to make tumors look like bacterium
Biotech veteran James Bianco, discusses his new Tampa based company, which is already in a trial designed to read out for potentially both accelerated and full approval. Coverage brought to you by
Nov 6
Miami Oncology Summit: Thoracic Medical Oncologist Estelamari Rodriguez discusses the latest in lung cancer treatments
She covers KRAS, ROS1, EGFR, and more. Coverage brought to you by
Nov 6
BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field
CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September. Coverage brought to you by
Nov 4
BIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in treatment-resistant type 2 diabetes
CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients. Coverage brought to you by
Nov 4
.png){kind=logo}
